Literature DB >> 16086366

Role for CXCR2 and CXCL1 on glia in multiple sclerosis.

Kakuri M Omari1, Gareth John, Richard Lango, Cedric S Raine.   

Abstract

As part of a need to understand myelin repair mechanisms, molecular pathways underlying oligodendrocyte behavior and central nervous system (CNS) remyelination are currently key topics in multiple sclerosis (MS). In the present study, we report expression of a chemoattractant receptor of the immune system, the chemokine receptor, CXCR2, on normal and proliferating oligodendrocytes in active MS lesions. Proliferating oligodendrocytes were occasionally associated with reactive astrocytes positive for CXCL1 (GRO-alpha), the ligand for CXCR2. CXCL1 expression was not seen on astrocytes in control and normal CNS tissue, while CXCR2 expression was constitutive on oligodendrocytes. At the functional level, following stimulation with the proinflammatory cytokine, interleukin-1beta (IL-1beta), we found high-level synthesis of CXCL1 by human fetal astrocytes in vitro. In contrast, human oligodendrocytes in culture expressed the receptor, CXCR2, constitutively. We propose that the concurrence of CXCR2 on oligodendrocytes and induced CXCL1 on hypertrophic astrocytes in MS provides a novel mechanism for recruitment of oligodendrocytes to areas of damage, an essential prerequisite for lesion repair in this devastating human condition. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16086366     DOI: 10.1002/glia.20246

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  48 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells.

Authors:  LiPing Liu; Lindsey Darnall; Taofang Hu; Karen Choi; Thomas E Lane; Richard M Ransohoff
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

3.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

Review 4.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

5.  Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2.

Authors:  De-Li Cao; Zhi-Jun Zhang; Rou-Gang Xie; Bao-Chun Jiang; Ru-Rong Ji; Yong-Jing Gao
Journal:  Exp Neurol       Date:  2014-05-20       Impact factor: 5.330

6.  CXCL1 and CXCL2 Inhibit the Axon Outgrowth in a Time- and Cell-Type-Dependent Manner in Adult Rat Dorsal Root Ganglia Neurons.

Authors:  Antonia Teona Deftu; Ruxandra Ciorescu; Roxana-Olimpia Gheorghe; Dan Mihăilescu; Violeta Ristoiu
Journal:  Neurochem Res       Date:  2019-08-17       Impact factor: 3.996

Review 7.  Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.

Authors:  Bridgette D Semple; Thomas Kossmann; Maria Cristina Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

Review 8.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

9.  CXCR2 signaling protects oligodendrocytes and restricts demyelination in a mouse model of viral-induced demyelination.

Authors:  Martin P Hosking; Emanuele Tirotta; Richard M Ransohoff; Thomas E Lane
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

10.  A protective role for ELR+ chemokines during acute viral encephalomyelitis.

Authors:  Martin P Hosking; Liping Liu; Richard M Ransohoff; Thomas E Lane
Journal:  PLoS Pathog       Date:  2009-11-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.